In patients with heart failure whose ejection fraction is greater than 40%, sacubitril/valsartan is beneficial.

Published Date: 26 May 2023

USA: Treatment with sacubitril/valsartan results in a greater decrease in plasma NT-proBNP in patients with an ejection fraction (EF) above 40%.

Read Full News

Latest News


News All Time

Featured News
Featured Articles
Featured Events
Featured KOL Videos

1.

Long Wait Times on the Other Side of the Pond: King Charles' Cancer Diagnosis.

2.

recognizing the mechanism by which the replication of the host cell is outperformed by the skin cancer virus.

3.

FINAL USPSTF RECOMMENDATIONS ON ANXIETY, DEPRESSION, AND SUIICIDAL RISK.

4.

Durvalumab Wins FDA Approval in Limited-Stage SCLC

5.

Telehealth in the pandemic era resulted in fewer therapy interruptions.


© Copyright 2026 Hidoc Dr. Inc.

Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
bot